Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback

Jefferies analyst Biren Amin reiterated his Buy rating and $43 price target on The Medicines Company (NASDAQ: MDCO) saying Alnylam Pharmaceuticals (NASDAQ: ALNY) set back has no read-through to the company's PCSK9 Program.

Amin commented, "ALNY announced that revusiran was stopped due to lack of a treatment benefit w/ an imbalance of deaths favoring the revusiran arm over placebo. The imbalance was not tx-related. As a result of ALNY's update, MDCO provided a safety update on ALN-PCSsc in which it reported no imbalances to date on peripheral neuropathy, liver toxicity, renal toxicity, and mortality from its 501-patient ORION-1 study. Data from this trial are expected at AHA on Nov 15."

MDCO last traded down 10.4% in pre-open trade to $34.50.

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Boston Scientific (BSX) PT Raised to $82 at Wells Fargo
• HSBC Upgrades UPS (UPS) to Buy, 'Back to earnings growth'